Adeza Appoints Greg Vontz to Board of Directors
01 Marzo 2006 - 3:00AM
Business Wire
Adeza (Nasdaq:ADZA) today announced the appointment of Greg Vontz
as an independent director of the company, increasing the size of
the Adeza board of directors to seven, with a six-member
independent majority. "We welcome Greg to our board and look
forward to calling upon his significant business expertise," said
Emory V. Anderson, president and chief executive officer. "His
accomplishments at large and small drug companies are testaments to
his abilities to set strategy and to build value." Mr. Vontz has 21
years of progressive business experience in the pharmaceutical and
biotechnology industries. Currently, he serves as president and
chief operating officer of Connetics Corporation (Nasdaq:CNCT), a
specialty pharmaceutical company focused on dermatology. Vontz
joined Connetics in 1999 as chief commercial officer and in 2001
was named executive vice-president and chief operating officer. He
added the title of president in February 2005. Prior to Connetics,
Mr. Vontz worked at Genentech, Inc. (NYSE:DNA) for 12 years, where
he held various business, sales and marketing positions, ultimately
serving as director of new markets and healthcare policy. He has
also held sales positions at Merck & Co., Inc. "In particular
Greg's strong background in sales and marketing will be valuable as
we continue to expand initiatives to support our strategy," said
Emory V. Anderson, president and chief executive officer. Mr. Vontz
received a BS in Chemistry from the University of Florida and an
MBA from the Haas School of Business at the University of
California, Berkeley. About Adeza Adeza designs, manufactures and
markets innovative products for women's health. Adeza's initial
focus is on reproductive healthcare, using its proprietary
technologies to predict preterm birth and assess infertility.
Adeza's principal product is a patented diagnostic test,
FullTerm(TM), The Fetal Fibronectin Test, which utilizes a
single-use, disposable cassette and is analyzed on Adeza's patented
TLiIQ(R) System. This product is approved by the U.S. Food and Drug
Administration (FDA) for use in assessing the risk of preterm
birth. Adeza also markets and sells the E-tegrity(R) Test, an
infertility-related test to assess receptivity of the uterus to
embryo implantation in women with unexplained infertility. More
information is available at www.adeza.com. Adeza cautions you that
statements included in this press release that are not a
description of historical facts may be forward-looking statements.
The inclusion of forward-looking statements should not be regarded
as a representation by Adeza that any of its plans will be
achieved. Actual results may differ materially from those set forth
in this release due to the risks and uncertainties inherent in
Adeza's business including, without limitation, statements about
its business strategy and the expansion of the indications for its
products. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Adeza undertakes no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof.
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Adeza Biomedical (MM) (NASDAQ): 0 recent articles
Más de Adeza Artículos de Noticias